Skip to main content
. 2020 Dec 26;10(1):58. doi: 10.3390/jcm10010058

Figure 2.

Figure 2

Relative blood volume between baseline and 1 month after intravitreal ranibizumab injection. (A) In the whole sample, we found no significant differences of relative flow volume (RFV) between baseline and 1 month after intravitreal ranibizumab injection (IRI) in the arteries of the non-occluded (p = 0.593) or occluded regions (p = 0.245). The veins of the non-occluded region showed significant differences in RFV between baseline and 1 month after IRI (p = 0.501), but the veins of the occluded region did not (* p = 0.029). (B) In the group with no recurrence of macula edema (nonrecurrent group, n = 24), we found no significant differences of RFV between baseline and 1 month after IRI in the arteries and veins of the non-occluded and occluded regions (arteries: p = 0.918, p = 0.904, respectively; veins: p = 0.641, p = 0.859, respectively). (C) In the group with recurrence of macular edema (recurrent group, n = 23), we found no significant differences in RFV between baseline and 1 month after IRI in the arteries of the non-occluded and occluded regions (p = 0.540, p = 0.090, respectively) or veins of the non-occluded region (p = 0.638); however, we did find a significant difference in RFV between baseline and 1 month after IRI in the veins of the occluded region (* p <0.001).